Ipamorelin

Ipamorelin is a small peptide that switches on the ghrelin receptor to trigger growth-hormone release, while avoiding other hormone side-effects.

It's studied in performance and recovery research — growth-hormone release that doesn't also raise cortisol, prolactin, or appetite.

Animal studies showed selective hormone release without appetite spikes. Human benefit is unproven.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

Ipamorelin is an investigational drug. It is not FDA-approved for human therapeutic or medical use.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Selective profile in preclinical literature.

• Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.